Aligos TherapeuticsALGS
13F holders, Q4 2024 (December 31)33holders +6
10new positions
6sold out
1famous investor
$39.84avg. 13F price*
At the end of Q4 2024, 33 institutions reported holding Aligos Therapeutics Inc. (ALGS) in their 13F filings, up 6 from Q3 2024. 10 opened new positions and 6 sold out. The largest holders were Adage Capital Partners Gp, L.L.C. ($12.9M), EcoR1 Capital, LLC ($10.2M) and Deep Track Capital, LP ($9.7M). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Aligos Therapeutics Inc.
- CUSIP
- 01626L204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $10.6M |
| Exits | 6 | $4.1M |
All 13F filers, Q3 2024 → Q4 2024: 435,405 shares bought and 511,070 shares sold, net −75,665 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 33 holders
| Adage Capital Partners Gp, L.L.C. | 0.02% | Add +48.5% | 325,000 | $12.9M |
| EcoR1 Capital, LLC | 0.41% | No change | 255,573 | $10.2M |
| Deep Track Capital, LP | 0.36% | No change | 244,110 | $9.7M |
| Vivo Capital, LLC | 0.63% | No change | 141,879 | $5.7M |
| Vanguard Group Inc. | 0.00% | Add +51.6% | 96,762 | $3.9M |
| Baker Bros. Advisors LP | 0.04% | No change | 83,055 | $3.3M |
| HHLR Advisors, LTD. | 0.11% | No change | 76,247 | $3.0M |
| Trexquant Investment LP | 0.03% | New | 69,050 | $2.8M |
| Ikarian Capital, LLC | 0.73% | New | 64,300 | $2.6M |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 0.04% | Reduce -40.2% | 40,096 | $1.6M |
| Avantax Advisory Services, Inc. | 0.01% | New | 30,570 | $1.2M |
| Geode Capital Management, LLC | 0.00% | Add +13.3% | 27,253 | $1.1M |
| Drive Wealth Management, LLC | 0.22% | New | 23,000 | $916K |
| Royal Bank of Canada | 0.00% | New | 23,008 | $916K |
| Wells Fargo & Company | 0.00% | New | 21,800 | $869K |
| Boothbay Fund Management, LLC | 0.02% | New | 18,543 | $739K |
| UBS Group AG | 0.00% | Add +110764.3% | 15,521 | $618K |
| Charles Schwab Investment Management Inc. | 0.00% | Add +19.3% | 14,286 | $569K |
| BlackRock, Inc. | 0.00% | Add +51.3% | 13,721 | $547K |
| Renaissance Technologies | 0.00% | Reduce -14.9% | 11,443 | $456K |
| State Street Corp. | 0.00% | New | 9,582 | $382K |
| Northern Trust Corp. | 0.00% | New | 5,157 | $205K |
| Morgan Stanley | 0.00% | Add +2312.7% | 3,233 | $129K |
| Golden State Wealth Management, LLC | 0.02% | — | 2,674 | $107K |
| AlphaMark Advisors, LLC | 0.02% | Add +1000.0% | 1,100 | $44K |
| Osaic Holdings, Inc. | 0.00% | Add +306.8% | 895 | $36K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +2073.3% | 652 | $26K |
| Bank of America Corp. | 0.00% | Reduce -95.8% | 285 | $11K |
| Spire Wealth Management | 0.00% | New | 200 | $8K |
| SBI Securities Co., Ltd. | 0.00% | — | 171 | $7K |
| JPMorgan Chase & Co. | 0.00% | No change | 26 | $1K |
| Elevation Wealth Partners, LLC | 0.00% | No change | 4 | $160 |
| BNP Paribas Financial Markets | 0.00% | No change | 3 | $120 |
"% of holder's portfolio" is ALGS's weight in each manager's 13F, not the share of Aligos Therapeutics Inc. the manager owns.